ARIAD to Present Preclinical Data on Multi-Targeted Kinase Inhibitor at 50th Ash Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 24, 2008 - ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the company and collaborating investigators from the Howard Hughes Medical Institute and Oregon Health & Science University Cancer Institute will present new data from preclinical studies on AP24534, a multi-targeted kinase inhibitor, at the 50th Annual Meeting of the American Society of Hematology (ASH) being held in San Francisco, California, December 6-9, 2008. The data to be presented relate to the potential utility of AP24534 in hematological malignancies, specifically chronic myeloid leukemia (CML) and acute myeloid leukemia (AML).
The schedule of presentations for AP24534 is as follows:
| Abstract Title: | “Potent Antitumor Activity of AP24534, an Orally Active Inhibitor of Bcr-Abl, Flt3 and Other Kinases, in Both in Vitro and in Vivo Models of Acute Myeloid Leukemia (AML)” | |
| Presenter: | Victor M. Rivera, Ph.D. | |
| Poster Session:
|
Acute Myeloid Leukemia - Biology and Pathophysiology Poster II | |
| Number: | #2932 | |
| Date/Time: | Monday, December 8, 2008 at 5:30 p.m. PT | |
| Location: | Moscone Center, Hall A | |
| Abstract Title: | “Complete Suppression of in Vitro Resistance by AP24534, a Pan-BCR-ABL Inhibitor”
|
|
| Presenter: | Thomas O'Hare, Ph.D. | |
| Poster Session: | Drug Resistance and New Drugs In Chronic Myelogenous Leukemia | |
| Number: | #726 | |
| Date/Time: | Monday, December 8, 2008 at 7:15 p.m. PT | |
| Location: | West Moscone Center, 3001-3003-3005 | |
ARIAD's second oncology product candidate, AP24534, is an investigational oral multi-targeted tyrosine kinase inhibitor that has broad potential applications in cancer. In preclinical studies, AP24534 has demonstrated potent inhibition of kinase targets associated with drug-resistant chronic myeloid leukemia and acute myeloid leukemia, as well as proliferation and angiogenesis in multiple solid tumors. In addition to an ongoing Phase 1 clinical study in hematological malignancies, further clinical development in patients with solid tumors is expected to begin in 2009. Additional information about the ongoing clinical trial can be found at http://www.clinicaltrials.gov.
About ARIAD
ARIAD is engaged in the discovery and development of breakthrough medicines to treat cancer by regulating cell signaling with small molecules. ARIAD is developing a comprehensive approach to patients with cancer that addresses the greatest medical need - aggressive and advanced-stage cancers for which current treatments are inadequate. ARIAD has a global partnership with Merck & Co., Inc. to develop and commercialize deforolimus, ARIAD's lead cancer product candidate, which is in Phase 3 clinical development. ARIAD's second oncology product candidate, oral AP24534, is a novel multi-targeted kinase inhibitor in Phase 1 clinical development in hematological cancers. ARIAD has an exclusive license to pioneering technology and patents related to certain NF-κB treatment methods, and the discovery and development of drugs to regulate NF-κB cell-signaling activity, which may be useful in treating certain diseases. Additional information about ARIAD can be found on the web at http://www.ariad.com.
Contact: ARIAD Pharmaceuticals, Inc.
Maria E. Cantor, 617-621-2208
Posted: November 2008
